France
Qynapse, founded in 2015, is pioneering the future of neuroimaging analysis with its innovative software platforms. Headquartered in France, the company also operates in the United States and Canada, and collaborates with a world-renowned team of scientific and clinical partners.
The company offers two main products: QyScore®, an FDA-cleared and CE-marked neuroimaging software platform, and QyPredict®, a predictive research-use-only platform. Both leverage proprietary Artificial Intelligence and machine learning to provide accurate, reliable insights into CNS disorders such as Alzheimer’s, multiple sclerosis, and Parkinson’s disease. These platforms are designed to enhance the precision of MRI scan readings and have the potential to significantly improve the outcomes of clinical trials.
Qynapse received its last known investment of $3.00M on 01 June 2021. With a proven track record of innovation and strategic partnerships, Qynapse is well-positioned to shape the future of diagnosis and treatment for central nervous system diseases.
